The VICC.ORG Directory of Cancers: Treatments, Services & Resources

Skin Cancers and Melanoma

The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma.


Clinical Trials for Skin Cancers and Melanoma

16 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TherapeuticVICCMEL12109
05/17/2013
A Phase III, Double-Blinded, Placebo-Controlled Study of Vemurafenib versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAFV600 Mutation-Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma
TherapeuticVICCMEL1290
02/06/2013
Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination with Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
TherapeuticVICCMEL12100
01/18/2013
A Randomized, Open-Label Phase 3 Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.
TherapeuticVICCMEL1256
12/06/2012
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence
TherapeuticVICCPHI1231
11/19/2012
Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma
TherapeuticVICCMEL1168
07/12/2012
An Open-label Multicenter Phase II Study of Continuous Oral Vemurafenib in Patients with Locally-Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF mutations other than V600E
TherapeuticVICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
TherapeuticVICCMEL1130
02/08/2012
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEXGM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
TherapeuticVICCMEL1036
10/24/2011
A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients with Unresectable Stage III or Stage IV Melanoma Disease
TherapeuticECOGMELE1609
09/08/2011
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
TherapeuticVICCMEL0759
08/01/2008
A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma
CorrelativeVICCMEL1081
09/28/2011
The High-Dose Aldesleukin (IL-2) "Select" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Advanced Melanoma
CorrelativeVICCMEL0287
05/06/2003
Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository
Epidemiology, Observation, OutcomesVICCMEL12117
02/18/2013
A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy
Screen, Detect, DiagnoseVICCMD1286
12/17/2012
Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib
Screen, Detect, DiagnoseVICCMEL09109
06/03/2010
Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

You do not have JavaScript enabled. This site works better with JavaScript turned on.